[go: up one dir, main page]

CA2554697A1 - Methodes de reduction de la liberation massive induite par l'alcool pour les formes posologiques orales de morphine a liberation soutenue - Google Patents

Methodes de reduction de la liberation massive induite par l'alcool pour les formes posologiques orales de morphine a liberation soutenue Download PDF

Info

Publication number
CA2554697A1
CA2554697A1 CA002554697A CA2554697A CA2554697A1 CA 2554697 A1 CA2554697 A1 CA 2554697A1 CA 002554697 A CA002554697 A CA 002554697A CA 2554697 A CA2554697 A CA 2554697A CA 2554697 A1 CA2554697 A1 CA 2554697A1
Authority
CA
Canada
Prior art keywords
morphine
sustained release
dosage form
release dosage
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002554697A
Other languages
English (en)
Inventor
Gayatri Sathyan
Nipun Davar
Linda Pors
Gemma Casadevall
Jayne Hastedt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of CA2554697A1 publication Critical patent/CA2554697A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA002554697A 2005-10-31 2006-07-31 Methodes de reduction de la liberation massive induite par l'alcool pour les formes posologiques orales de morphine a liberation soutenue Abandoned CA2554697A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US73199505P 2005-10-31 2005-10-31
US60/731,995 2005-10-31
US80201706P 2006-05-18 2006-05-18
US60/802,017 2006-05-18

Publications (1)

Publication Number Publication Date
CA2554697A1 true CA2554697A1 (fr) 2007-04-30

Family

ID=36758362

Family Applications (6)

Application Number Title Priority Date Filing Date
CA002554874A Abandoned CA2554874A1 (fr) 2005-10-31 2006-07-31 Methodes de reduction de la liberation massive induite par l'alcool pour les formes posologiques orales d'hydromorphone a liberation soutenue
CA002554698A Abandoned CA2554698A1 (fr) 2005-10-31 2006-07-31 Methodes de reduction de la liberation massive induite par l'alcool pour les formes posologiques orales d'hydrocodone a liberation soutenue
CA002554701A Abandoned CA2554701A1 (fr) 2005-10-31 2006-07-31 Methodes de reduction de la liberation massive induite par l'alcool pour les formes posologiques orales d'opioide a liberation soutenue
CA002554684A Abandoned CA2554684A1 (fr) 2005-10-31 2006-07-31 Methodes de reduction de la liberation massive induite par l'alcool pour les formes posologiques orales d'oxycodone a liberation soutenue
CA002554693A Abandoned CA2554693A1 (fr) 2005-10-31 2006-07-31 Methodes de reduction de la liberation massive induite par l'alcool pour les formes posologiques orales d'oxymorphone a liberation soutenue
CA002554697A Abandoned CA2554697A1 (fr) 2005-10-31 2006-07-31 Methodes de reduction de la liberation massive induite par l'alcool pour les formes posologiques orales de morphine a liberation soutenue

Family Applications Before (5)

Application Number Title Priority Date Filing Date
CA002554874A Abandoned CA2554874A1 (fr) 2005-10-31 2006-07-31 Methodes de reduction de la liberation massive induite par l'alcool pour les formes posologiques orales d'hydromorphone a liberation soutenue
CA002554698A Abandoned CA2554698A1 (fr) 2005-10-31 2006-07-31 Methodes de reduction de la liberation massive induite par l'alcool pour les formes posologiques orales d'hydrocodone a liberation soutenue
CA002554701A Abandoned CA2554701A1 (fr) 2005-10-31 2006-07-31 Methodes de reduction de la liberation massive induite par l'alcool pour les formes posologiques orales d'opioide a liberation soutenue
CA002554684A Abandoned CA2554684A1 (fr) 2005-10-31 2006-07-31 Methodes de reduction de la liberation massive induite par l'alcool pour les formes posologiques orales d'oxycodone a liberation soutenue
CA002554693A Abandoned CA2554693A1 (fr) 2005-10-31 2006-07-31 Methodes de reduction de la liberation massive induite par l'alcool pour les formes posologiques orales d'oxymorphone a liberation soutenue

Country Status (11)

Country Link
BG (1) BG1070U1 (fr)
CA (6) CA2554874A1 (fr)
CZ (1) CZ19137U1 (fr)
DK (1) DK200600189U3 (fr)
FI (1) FI7357U1 (fr)
GB (1) GB0612326D0 (fr)
IE (1) IES20060507A2 (fr)
NL (1) NL1032148C1 (fr)
NO (1) NO20063233L (fr)
SE (1) SE0601589L (fr)
SK (1) SK5202Y1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140248343A1 (en) * 2007-08-13 2014-09-04 Inspirion Delivery Technologies, Llc Abuse resistant forms of extended release morphine, method of use and method of making
US10172842B2 (en) * 2015-09-11 2019-01-08 PharmaDax Inc. Sustained release oral dosage form containing dalfampridine
US10420726B2 (en) 2013-03-15 2019-09-24 Inspirion Delivery Sciences, Llc Abuse deterrent compositions and methods of use
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018390826B2 (en) 2017-12-20 2024-09-12 Purdue Pharma L.P. Abuse deterrent morphine sulfate dosage forms

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10729656B2 (en) 2007-08-13 2020-08-04 Ohemo Life Sciences Inc. Abuse resistant forms of immediate release oxycodone, method of use and method of making
US11045422B2 (en) 2007-08-13 2021-06-29 Oheno Life Sciences, Inc. Abuse resistant drugs, method of use and method of making
US11291634B2 (en) 2007-08-13 2022-04-05 OHEMO Life Sciences, Inc. Abuse resistant forms of extended release oxymorphone, method of use and method of making
US10688052B2 (en) 2007-08-13 2020-06-23 Inspirion Delivery Sciences Llc Abuse resistant forms of extended release oxymorphone, method of use and method of making
US10688055B2 (en) 2007-08-13 2020-06-23 Inspirion Delivery Sciences, Llc Abuse resistant forms of extended release morphine, method of use and method of making
US10688053B2 (en) 2007-08-13 2020-06-23 Inspirion Delivery Sciences, Llc Abuse resistant forms of extended release hydrocodone, method of use and method of making
US10688051B2 (en) 2007-08-13 2020-06-23 Inspirion Delivery Sciences Llc Abuse resistant forms of extended release oxycodone, method of use, and method of making
US10688054B2 (en) 2007-08-13 2020-06-23 Inspirion Delivery Sciences Llc Abuse resistant forms of extended release morphine, method of use and method of making
US10695298B2 (en) 2007-08-13 2020-06-30 Inspirion Delivery Sciences, Llc Abuse resistant forms of extended release hydromorphone, method of use and method of making
US10729657B2 (en) 2007-08-13 2020-08-04 Ohemo Life Sciences Inc. Abuse resistant forms of extended release morphine, method of use and method of making
US11285112B2 (en) 2007-08-13 2022-03-29 Oheno Life Sciences, Inc Abuse resistant forms of immediate release oxymorphone, method of use and method of making
US11278500B2 (en) 2007-08-13 2022-03-22 OHEMO Life Sciences, Inc. Abuse resistant forms of extended release hydrocodone, method of use and method of making
US10702480B2 (en) * 2007-08-13 2020-07-07 OHEMO Life Sciences, Inc. Abuse resistant forms of extended release morphine, method of use and method of making
US10736850B2 (en) 2007-08-13 2020-08-11 Ohemo Life Sciences Inc. Abuse resistant oral opioid formulations
US10736852B2 (en) 2007-08-13 2020-08-11 OHEMO Life Sciences, Inc. Abuse resistant oral opioid formulations
US10736851B2 (en) 2007-08-13 2020-08-11 Ohemo Life Sciences Inc. Abuse resistant forms of extended release morphine with oxycodone, method of use and method of making
US20140248343A1 (en) * 2007-08-13 2014-09-04 Inspirion Delivery Technologies, Llc Abuse resistant forms of extended release morphine, method of use and method of making
US11191730B2 (en) 2007-08-13 2021-12-07 Ohemo Life Sciences Inc. Abuse resistant forms of immediate release hydromorphone, method of use and method of making
US10420726B2 (en) 2013-03-15 2019-09-24 Inspirion Delivery Sciences, Llc Abuse deterrent compositions and methods of use
US11571390B2 (en) 2013-03-15 2023-02-07 Othemo Life Sciences, Inc. Abuse deterrent compositions and methods of use
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
US10172842B2 (en) * 2015-09-11 2019-01-08 PharmaDax Inc. Sustained release oral dosage form containing dalfampridine

Also Published As

Publication number Publication date
SK5202Y1 (en) 2009-06-05
FIU20060296U0 (fi) 2006-07-12
CA2554684A1 (fr) 2007-04-30
CA2554693A1 (fr) 2007-04-30
SE0601589L (sv) 2007-05-01
NO20063233L (no) 2007-05-02
GB0612326D0 (en) 2006-08-02
IES20060507A2 (en) 2007-05-30
CA2554701A1 (fr) 2007-04-30
CA2554698A1 (fr) 2007-04-30
SK50572006U1 (en) 2009-01-07
FI7357U1 (fi) 2007-01-16
NL1032148C1 (nl) 2006-11-17
DK200600189U3 (da) 2007-02-23
CA2554874A1 (fr) 2007-04-30
CZ19137U1 (cs) 2008-12-08
BG1070U1 (bg) 2008-06-30

Similar Documents

Publication Publication Date Title
AU2006308718B2 (en) Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms
US20120283275A1 (en) Methods and dosage forms for reducing side effects of benzisozazole derivatives
US20090227605A1 (en) Enhanced efficacy benzisoxazole derivative dosage forms and methods
US20070004797A1 (en) Methods and dosage forms for reducing side effects of carbamate compounds
US20070298105A1 (en) Methods of treating conditions by sustained release administration of benzimidazole derivatives
WO2006085856A1 (fr) Procedes et formes pharmaceutiques destines a reduire les effets secondaires des derives de benzisozazole
EP1849460A2 (fr) Procédé pour la reduction du "dose dumping" induit par l'alcohole dans des préparations à liberation retardeé des opioides
CA2554697A1 (fr) Methodes de reduction de la liberation massive induite par l'alcool pour les formes posologiques orales de morphine a liberation soutenue
ITTO20060161U1 (it) Procedimenti per ridurre il rilascio precipitoso indotto da alcool per forme di dosaggio orali a rilascio prolungato di oppioidi
IES84730Y1 (en) Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms
HK1115070B (en) Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms
ITTO20060112U1 (it) Procedimenti per ridurre il rilascio precipitoso indotto da alcool per forme di dosaggio orali a rilascio prolungato di oppioidi.
HK1106451B (en) Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead